Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

ConditionsAML ALL MDS MPD Withou Myelofibrosis NHL or HL Inherited Metabolic Disorders Hemoglobinopathies Bone Marrow Failure HLH

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

AgeUp to 21

SponsorMemorial Sloan Kettering Cancer Center

About this trial

This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

Eligibility criteria

Qualifiers

Known prior diagnosis of myelodysplasia (MDS) or myeloproliferative disorder (MPS).

Therapy-related AML (t-AML).

White cell count at presentation > 100,000.

Presence of extramedullary leukemia at diagnosis.

Disqualifiers

Inadequate performance status/ organ function.

Advanced metabolic disease (EBMT handbook).

Active CNS leukemic involvement.

Indolent NHL or Hodgkin lymphoma with progression of disease after most recent salvage chemotherapy.

Trial design

Treatments tested in this trial

Clofarabine
Fludarabine
Busulfan
Cyclosporine-A
Mycophenolate Mofetil
Cord Blood Graft

Treatment groups

31 Participants

are divided into 2 treatment groups

Locations

Memorial Sloan Kettering Cancer Center10065, New YorkNew York, United States

Sponsors and collaborators

Memorial Sloan Kettering Cancer Center

Lead sponsor

Source ClinicalTrials.gov